| |
HBV Meeting Paris: Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: Combined intrahepatic results from the clinical trials MYR203 and MYR301
|
| |
| |
International HBV Meeting; September 18-22, 2022; Paris, France
Lena Allweiss, Annika Volmari, Yvonne Ladiges, Corinna Eggers, Katrin Schöneweis, VithikaSuri, Jeffrey Wallin, Heiner Wedemeyer, Stephan Urban, Marc Lütgehetmann, Jan-Hendrik Bockmann, Maura Dandri
|
|
| |
| |
|
|
|
